Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

Mesoblast Phase III Cell Therapy Shows Promise Against Heart Failure  

Banner
Anna Osborne
28 February 2023
SHARE NOW
Allogeneic
Cell Therapy
Clinical Trials
Regulatory & Standards
Global leader in allogeneic cellular medicines for inflammatory diseases Mesoblast has announced that the Phase III (DREAM-HF) trial of its mesenchymal precursor cell therapy (MPCs: rexlemestrocel-L) strengthened heart function in patients with chronic heart failure (CHF).

Data from Mesoblast’s DREAM-HF Phase III trial – a randomized, double-blind, controlled study of 537 patients with CHF caused by reduced ejection fraction (HFrEF) – has been presented in The Journal of the American College of Cardiology (JACC), a premier peer-reviewed journal for cardiovascular medicine.

The patient population enrolled across 51 sites in North America, received a single intra-myocardial injection of 150 million cells of rexlemestrocel-L. Results at a mean follow-up of 30 months demonstrated that:

  • Left ventricular ejection fraction (LVEF) improved over 12 months to a significantly greater extent than controls.
  • All patients had a reduced risk of myocardial infarction (MI) or stroke of 57%. This increased to 75% in patients with inflammation.
  • The time-to-first major adverse cardiac event (MACE), which included cardiovascular death, MI, or stroke, was reduced by 28% in all patients. Again this increased to 37% in patients with inflammation.

How are you enjoying this news article? Let us know your thoughts, here >>

“We are very encouraged by these study data that indicate the potential of our allogeneic cellular therapy to address the major areas of unmet need in heart failure patients where conventional treatments are not effective. Improvement in LVEF at 12 months may be a functional surrogate endpoint for rexlemestrocel-L’s subsequent benefits on long-term MACE outcomes and survival in this high-risk patient population with chronic heart failure,” commented Dr. Silviu Itescu, Mesoblast, CEO.

MPC therapy appears to act as an immune modulator, reducing inflammation both locally in the cardiac muscle, and throughout the blood vessels of the body.

When activated rexlemestrocel-L strengthens cardiac muscle, protecting it from death, increasing microvascular blood flow, and improving cardiac energetics. In the large blood vessels outside the heart, they potentially decrease plaque instability.

Following the publication of its positive DREAM-HF results, Mesoblast released plans to meet with the FDA in Q2 2023 to discuss the potential pathway to achieve marketing approval in HFrEF for this previously RMAT-designated allogeneic cell therapy.

“MPC therapy could change the future of cardiovascular care for patients with heart failure due to inflammation,” notes Dr. Joseph G. Rogers, CEO and President of The Texas Heart Institute.

Source: Mesoblast asx announcement

 


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022